ArticleDrug delivery and translational research2026
Mannosylated fisetin/carveol lipid nanocapsules: brain-targeted dual therapy for modulation of epileptogenesis and cognitive deficits.
Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacological treatment of epilepsy is challenged by several barriers with the blood brain barrier (BBB) imposing the utmost restrictions to brain drug delivery. Antiepileptic drugs aim to reduce seizures frequency and severity while exerting minimal toxic effects. Herein, the merits of phytomedicine and brain targeted nanocarriers were combined for the control of seizures in a chronic epilepsy model. Fisetin (FS); a polyphenol and carveol (CAR); a limonene monoterpenoid were selected for their neuroprotective roles and co-loaded into lipid nanocapsules (FS/CAR@LNC). This was further decorated with mannose by post insertion targeting glucose transporter (GLUT-1) overexpressed on BBB (MAN-FS/CAR@LNC). The optimized MAN-FS/CAR@LNC revealed good colloidal properties with particle size (53.17 ± 4.06 nm), and low polydispersity index (0.11) and 26.9 ± 1.05 mV zeta potential. A high entrapment efficiency exceeding 99% and sustained drug release profile over 72 h were observed for both FS and CAR. In the in vivo imaging system (IVIS), MAN-FS/CAR@LNC attained 1.3-fold increase in fluorescence intensity at 5 h interval compared to FS/CAR@LNC. Following intraperitoneal administration in PTZ- induced chronic epilepsy mouse model, MAN-FS/CAR@LNC achieved maximal control of epileptic seizures accompanied with rehabilitation of locomotion, depressive and anxiety like-behaviors compared to FS/CAR and FS/CAR@LNC. Similarly, analysis of biomarkers reflecting depression and anxiety actions (brain-derived neurotrophic factor; BDNF, serotonin and glutamate) together with inflammatory markers (IL-6 and IL-1ꞵ) and histopathological assessment affirmed MAN-FS/CAR@LNC excelling in enhancing LNC brain targetability and hence seizures control. In conclusion, FS/CAR co-therapy aided with mannosylated LNC could present a compelling podium for the effective management of CNS disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.